Cencora (AmerisourceBergen)COR
Recorded

Cencora (AmerisourceBergen) 2026 Q4 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ4 2026Duration55 minParticipants14

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Hello, everyone. Thank you for joining us, and welcome to the Cencora Inc. Fiscal 2026 Fourth Quarter Earnings Call. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. I will now hand the conference over to Bennett Murphy.

Bennett MurphySVP of Investor Relations and Enterprise Productivity

Bennett, please go ahead. Good morning, good afternoon, and thank you all for joining us for this conference call to discuss Cencora's Fiscal 2026 Fourth Quarter and Full Year Results.

Bennett MurphySVP of Investor Relations and Enterprise Productivity

I am Bennett Murphy, Senior Vice President, Investor Relations and Enterprise Productivity. Joining me today are Bob Mauch, President and CEO, and Eva Boratto, Executive Vice President and CFO. On today's call, we will be discussing non-GAAP financial measures. Reconciliations of these measures to GAAP are provided in today's press release, which is available on our website at investor.cencora.com. We have also posted a slide presentation to accompany today's press release on our investor website. Alongside these materials, we are providing recast financials in our new segments for fiscal 2025 and fiscal 2026 in Form 8-K that will also be available on our investor relations website.

Bennett MurphySVP of Investor Relations and Enterprise Productivity

During this conference call, we will discuss forward-looking statements about our business and financial expectations on adjusted non-GAAP basis, including but not limited to EPS, operating income, and income taxes. Forward-looking statements are based on management's current expectations and are subject to uncertainty and change. For a discussion of key risks and assumptions, we refer you to today's press release and our SEC filings, including our most recent 10-Q. Cencora assumes no obligation to update any forward-looking statements, and this call cannot be rebroadcast without the permission of the company. You will have an opportunity to ask questions after today's remarks by management. We ask you to limit your questions to one per participant in order for us to get to as many as possible within the hour. With that, I will turn the call over to Bob.

Bob MauchPresident and CEO

Thank you, Bennett. Hi, everyone, and thank you for joining Cencora's Fiscal 2026 Fourth Quarter and Full Year Earnings Call. I want to begin by thanking our team members. Throughout the fiscal year, their commitment to our purpose and dedication to our customers fueled our performance as we delivered adjusted operating income growth of 14% and adjusted diluted EPS of $17.97, up 12%. Our fiscal 2026 performance demonstrates the strength of our business and the progress we have made with leadership and specialty and a portfolio increasingly aligned to the areas where we can create the greatest long-term value. We enter fiscal 2027 with momentum and greater operational and strategic focus. The outlook reflects our confidence and is aligned with our long-term targets when excluding the businesses in Other.

Bob MauchPresident and CEO

This morning, I will focus on two areas: the strategic progress delivered in fiscal 2026 and how our updated operating model will strengthen execution, customer focus, and visibility for investors. I will begin with the strategic progress delivered in fiscal 2026. Two years ago, we introduced a refined strategy to lead with market leaders, strengthen our position in specialty, and enhance patient access to pharmaceuticals. In fiscal 2026, we advanced each priority, delivered another year of record results, and expanded capabilities to support patient access to innovation in the specialty pharmaceutical market, where growth has been twice that of the broader market over the past five years. Our MSO platform is one important example. In February, we completed our acquisition of OneOncology, expanding our position in one of healthcare's fastest-growing areas.

Bob MauchPresident and CEO

Together, OneOncology and Retina Consultants of America deepen our relationships with community-based specialists and strengthen our ability to support pharmaceutical-centric care closer to where patients live. During the fiscal year, we continued to build the MSO platform, including the announced acquisition of EyeSouth's retina business in March, and most recently, our agreement to acquire a majority interest in American Oncology Network. These additions will expand the capabilities and reach of a platform built to help independent specialty practices thrive, improve patient access to high-quality care, and create opportunities to support pharmaceutical companies across the product lifecycle. In fact, at RCA, we participate in the vast majority of retina clinical trials, completing over 40,000 research-related visits annually. OneOncology has supported more than 130 pharmaceutical partners with their clinical trials to date.

Bob MauchPresident and CEO

As we have invested in the businesses aligned with our pharmaceutical-centric strategy, we have also taken decisive action on businesses that do not align, concentrating our capital and leadership attention where Cencora is most differentiated. Over the course of the year, we entered into agreements or completed divestitures for all the businesses within Other. While these actions can cause near-term financial headwinds, they allow us to direct our resources towards the areas where we can create the greatest value for customers and shareholders over the long term. The same discipline guiding our portfolio informs how we operate. This morning, we introduced an updated operating model aligned with our strategy and the customers we serve. Our pharmaceutical-centric strategy is focused on strengthening our leadership in specialty and delivering greater value across pharmaceutical services.

Bob MauchPresident and CEO

As the needs of manufacturers and providers evolve, we are adapting our organization to better support them while preserving the benefits of Cencora's scale, infrastructure, and expertise. I believe this operating model will make Cencora more effective in three ways: enhancing our strategic and operational execution, further elevating the voice of our customers, and providing increased visibility for our shareholders. Informed by our updated operating model, we have created two new reporting segments. Specialty Pharmaceutical and Provider Services brings together our specialty capabilities in an integrated growth platform, supporting innovation from pharmaceutical manufacturers to physician providers. Pharmaceutical Distribution and Services, organized around our broad portfolio of customers and the services we provide, while leveraging our scale to deliver sustained growth and strong cash flow generation, powering investments across the enterprise. Now I will share a bit more about each segment. Starting with Specialty Pharmaceutical and Provider Services.

Bob MauchPresident and CEO

We are connecting capabilities across clinical trial logistics, commercialization, specialty distribution, GPO, and practice management to support innovative therapies from development to delivery to patient. That role is becoming more important, with specialty biologics now accounting for more than half of all pharmaceutical spending in the U.S., up 80% in five years. With over 100 new products expected to launch through 2030, oncology illustrates the growing need for specialized clinical logistics, distribution, and provider support as the pipeline expands and therapies become more complex. These are capabilities Cencora has built at scale through focused investments. With specialty logistics operations across more than 50 countries and multinational 3PL solutions in the U.S. and Europe, we can support pharmaceutical partners as they bring complex therapies to patients across markets. Our role does not end when a therapy reaches its destination.

Bob MauchPresident and CEO

As more specialty care is delivered in community settings, providers are managing increasing clinical and administrative demands. Through our MSOs, we help independent specialty physicians manage clinical and administrative complexity, expand access to research, and remain focused on patient care. Our agreement to acquire a majority interest in AON extends the platform through a physician-led network and a longstanding Cencora partner. Bringing these businesses together deepens our relationships with manufacturers and providers while giving investors a clearer view of the growth potential of our specialty platform. Within Pharmaceutical Distribution and Services, our scale provides us with deep understanding of trends across the healthcare ecosystem, which we use to drive differentiated value to customers. We deliver over 100 million packages annually, shipping nearly 5 million units each day, giving our leaders firsthand insight into the needs of manufacturers, providers, pharmacies, and patients.

Bob MauchPresident and CEO

Combining our scale, our sourcing expertise, and customer-centric partnerships with pharmacies and health systems, large and small, we strengthen their operations, support their growth, and ensure continued patient access. Two recent customer events illustrate how their perspective shape our priorities. At our Health Systems National Summit, health systems leaders discussed how connecting pharmacy, supply chain, technology, and care delivery leads to better decisions for patients and their organizations. These are all areas where our Accelerate Pharmacy Solutions help our health systems customers. At ThoughtSpot, our annual trade show for Good Neighbor independent pharmacies, we came together with more than 3,000 attendees, introducing novel solutions, including AI-powered tools designed to help pharmacies run more efficiently, free up time for patient care, and create new growth opportunities.

Bob MauchPresident and CEO

At both our Health Systems National Summit and ThoughtSpot, I heard customers emphasize that specialty is becoming a larger and more complex part of patient care, reinforcing the importance of specialty growth and solutions across both reporting segments. The scale of this opportunity is increasingly visible in our results. We expect specialty distribution revenue to reach approximately $100 billion in fiscal 2027. Combined with our broader manufacturer and provider capabilities, this makes specialty a central driver of Cencora's long-term growth. In summary, we exit fiscal 2026 with record results and a stronger platform for growth, supported by our scale, specialty capabilities, and an operating model aligned to how we create value. With that, I'll turn the call over to Eva to discuss our fourth quarter and fiscal 2026 results, as well as our fiscal 2027 guidance.

Eva BorattoEVP and CFO

Eva? Thanks, Bob. Good morning, everyone.

Eva BorattoEVP and CFO

As Bob highlighted and we shared in our press release this morning, we have introduced a new organizational and financial reporting structure designed to strengthen our execution and provide additional performance visibility to our shareholders. Through our new segments, we will highlight the significant opportunity we have to utilize our end-to-end specialty capabilities to deliver value up and downstream while driving sustainable growth powered by our scale and efficient pharmaceutical distribution foundation. In addition to reiterating Cencora's long-term growth algorithm of 7%-10% operating income growth and 10%-14% EPS growth, we are introducing targets for our new segments. For the Pharmaceutical Distribution and Services segment, we expect long-term operating income to grow in the mid-single digits. For the Specialty Pharmaceutical and Provider Services segment, we expect long-term operating income growth in the mid-teens.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day